All In Biotech

Free tool

FAERS Monitor: Natesto

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205488 or its brand name (Natesto, Testosterone). Reports on generic versions are filed under their own applications.

Reports

19,198

Serious

10,945

57% of reports

Hospitalization

4,611

Death reported

780

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,489
  • off label use1,238
  • fatigue1,186
  • nausea862
  • headache788
  • pain777
  • diarrhoea630
  • anxiety614
  • asthenia599
  • arthralgia598
  • dizziness596
  • dyspnoea552
  • insomnia517
  • weight decreased433
  • depression428

Reports by year received

View as table
YearReports
2004169
2005126
2006139
2007156
2008188
2009248
2010307
2011334
2012875
2013367
2014556
20151,113
20161,060
2017984
20181,193
20191,247
20201,199
20211,219
20221,422
20231,553
20241,642
20251,729
20261,372

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anxietySignal6142.42.2489
insomniaSignal5172.12.0312
depressionSignal4282.11.9235
asthenia5991.71.6194
weight decreased4331.71.5126
fatigue1,1861.71.6330
arthralgia5981.61.5128
off label use1,2381.51.5251
pain7771.41.386
headache7881.41.384
dizziness5961.31.244
drug ineffective1,4891.21.272
nausea8621.21.128
diarrhoea6301.11.03
dyspnoea5521.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.